We thank Delaloge and DeForceville¹ for raising several important points in their Comment on results from LOTUS,² a randomised, phase 2 trial investigating the addition of ipatasertib to paclitaxel as first-line therapy for metastatic triple-negative breast cancer. Specifically, they expressed concern over tissue-based diagnostics, given the spatial and temporal heterogeneity observed in triple-negative breast cancer. They remarked that if, as suggested in LOTUS, genomic alterations are the preferred biomarker, circulating tumour (ct) DNA methods might be useful in improving therapeutic targeting.

中文翻译：

---

LOTUS中基于血浆和基于组织的下一代测序之间的一致性

我们感谢Delaloge和DeForceville ¹在他们对LOTUS的结果的评论中提出了几个要点，^2这是一项随机的2期临床试验，研究了在紫杉醇中加用ipatasertib作为转移性三阴性乳腺癌的一线治疗。具体而言，鉴于三阴性乳腺癌中观察到的时空异质性，他们对基于组织的诊断表示关注。他们指出，如果像LOTUS中所建议的那样，基因组改变是首选的生物标志物，则循环肿瘤（ct）DNA方法可能对改善治疗靶向性有用。